Recombinant Anti-CD20 x Anti-CD22 Bispecific Antibody (Triple Body) is designed to be expressed as two polypeptide chains respectively. The Fd fragment and LC from an anti-CD20 antibody are both extended with the scFv fragment from an anti-CD22 antibody. This BsAb is designed for the research of Lymphoma; Leukemia; Antoimmune disease; Immune dysfunction disease therapy.
There are currently no customer reviews or questions for Recombinant Anti-CD20 x Anti-CD22 Bispecific Antibody (Triple Body) (TRIB-049). Click the button below to contact us or submit your feedback about this product.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRYSERVICES
PRODUCTS
PLATFORMS